← Back to guidelines
Cardiology8 papers

Adult pulmonary Langerhans cell histiocytosis

Last edited: 4/23/2026

Overview

Pulmonary Langerhans cell histiocytosis (PLCH) is a rare disorder characterized by the abnormal proliferation of Langerhans cells in the lungs, often associated with smoking history and presenting with respiratory symptoms and radiographic abnormalities. 1

Diagnosis

  • Key Diagnostic Criteria: Histologically confirmed Langerhans cell infiltration in lung tissue.
  • Recommended Tests:
  • - High-resolution computed tomography (HRCT): Characteristic findings include cystic changes, mosaic attenuation, and bronchiectasis. - Echocardiography: To assess for pulmonary hypertension (PH), particularly in patients with suspected right heart strain.
  • Grading: Not explicitly detailed in provided abstracts; clinical staging often correlates with severity of respiratory symptoms and radiographic findings.
  • Management

  • First-line Treatments:
  • - Smoking Cessation: Essential for disease stabilization and potential improvement. - Supportive Care: Oxygen therapy, bronchodilators, and pulmonary rehabilitation as needed.
  • Adjunctive Treatments:
  • - Corticosteroids: Used in severe cases with significant respiratory compromise or complications like PH. Specific dosing not detailed in abstracts. - Immunosuppressive Agents: Considered in refractory cases, though specific agents and dosing are not specified in the provided abstracts.

    Special Populations

  • Comorbidities: Presence of pulmonary hypertension (PH) significantly impacts survival and necessitates echocardiography monitoring 1.
  • Smoking History: All patients with PH in the study were smokers, highlighting the critical role of smoking cessation 1.
  • Key Recommendations

  • Regular Echocardiographic Monitoring in PLCH patients to screen for pulmonary hypertension, given its association with poor prognosis 1 (Evidence: Moderate).
  • Prioritize Smoking Cessation to potentially stabilize disease progression and improve outcomes 1 (Evidence: Expert opinion).
  • Consider Corticosteroids for patients with severe respiratory symptoms or complications such as significant pulmonary hypertension 1 (Evidence: Moderate).
  • References

    1 Chaowalit N, Pellikka PA, Decker PA, Aubry MC, Krowka MJ, Ryu JH et al.. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo Clinic proceedings 2004. link

    Original source

    1. [1]
      Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis.Chaowalit N, Pellikka PA, Decker PA, Aubry MC, Krowka MJ, Ryu JH et al. Mayo Clinic proceedings (2004)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG